Chi Young Ok, M.D.

Peer-Reviewed Articles

1. Wei Q, Medeiros LJ, Loghavi S, Leighton JS, Hu S, Toruner GA, Ok CY, Kanagal-Shamanna R, Xu J, Garcia-Manero G, Tang G. Chromoanagenesis in Myelodysplastic Syndromes Is Associated With Highly Complex Karyotype, TP53 Disruption, and Dismal Prognosis. Modern Pathology 39(8):101031, 2026. e-Pub 2026. PMID: 42320760.
2. Wang SA, Ok CY, Tsai HK, Loayza N, Daneshpajouhnejad P, Seth N, Cantu MD, Bagg A, Tam W, Weinberg O, Barone PD, Geyer JT, Lindsley CR, Montalban-Bravo G, Simon CR, Arber DA, Bueso-Ramos CE, Hsi ED, Foucar K, Orazi A, Patnaik MM, Hasserjian RP, Reichard KK. Isolated KRAS and NRAS mutations in adults with monocytosis and/or cytopenia(s). Haematologica 111(6):2070-2079, 2026. e-Pub 2026. PMID: 41437825.
3. Tang, G, Reynolds, A, Ravandi-Kashani, F, Medeiros, LJ, Kornblau, SM, Jabbour, EJ, Jain, N, Short, NJ, Hu, S, Wei, Q, Loghavi, S, Ok, CY, Toruner, GA, Ling, J, Liang, S, Verma, T, Zou, Y, Wang, S. Comprehensive Cytogenomic Profiling of T-Lymphoblastic Leukemia Using Optical Genome Mapping, Karyotyping, and Next-Generation Sequencing. Modern Pathology 39(5), 2026. e-Pub 2026. PMID: 41796805.
4. Wang, S, Li, S, Wang, W, Xu, J, Thakral, B, Hu, S, Ok, CY, Jia, F, Jorgensen, JL, Medeiros, LJ, Ravandi-Kashani, F, Short, NJ, Loghavi, S. Technical and Clinical Validity of Assessing Measurable Residual Disease by Multicolor Flow Cytometry in an Unselected Acute Myeloid Leukemia Patient Cohort. Archives of Pathology and Laboratory Medicine 150(1):72-80, 2026. e-Pub 2026. PMID: 40522873.
5. Wang W, Cai Q, Liu Y, Nie L, Lee H, Yan F, Fei Y, Yao Y, Li Y, Tan L, Lorenzi PL, Wang Y, Yao J, Chen Z, McIntosh J, Yu CT, Jain P, Jiang VC, Vargas J, Li X, Zhang T, Li S, Santos DA, Thirumurthi S, Seeley E, Simon LM, Flowers CR, Ok CY, Wang L. TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma. Blood 146(21):2544-2560, 2025. e-Pub 2025. PMID: 40700581.
6. Ok CY, Natu A, Daneshpajouhnejad P, Fathalla LA, Symes E, Barone PD, Shestakova A, Foucar K, Bueso-Ramos CE, Montalban Bravo G, Orazi A, Patnaik MM, Hasserjian RP, Arber DA, Geyer JT, Bagg A, Reichard KK, Wang S. Chronic myelomonocytic leukemia in the young (aged 50 years and younger). Cancer 131(22), 2025. e-Pub 2025. PMID: 41236405.
7. Nirmalanantham P, Quesada AE, Ghosh A, Lin P, Ok CY, Yang RK, Fang H, Garces S, Kanagal Shamanna R, Loghavi S, Routbort MJ, Yin CC, Wei W, Pasyar S, Bassett Jr R, El Hussein S, Jain N, Burger JA, Wierda WG, Wang S, Bueso-Ramos CE, Patel KP, Medeiros LJ, Jelloul FZ. Mutational Landscape and Clinical Impact of SPEN Mutations in Patients with Chronic Lymphocytic Leukemia. Cancers 17(21), 2025. e-Pub 2025. PMID: 41228377.
8. Ok CY, Tang G, Loghavi S, Hu S, Wei Q, Quesada AE, Routbort MJ, Kanagal Shamanna R, Yin CC, Sarami I, Garces S, Agarwal N, Luthra R, Fang H, Jelloul FZ, Bryan J, Medeiros LJ, Patel KP, Toruner GA. Comparative Analysis of Targeted RNA-Seq and Optical Genome Mapping for Detecting Gene Rearrangements in Acute Leukemia. Cancers 17(21), 2025. e-Pub 2025. PMID: 41228256.
9. Wei Q, Wang S, Garcia-Manero G, Kanagal Shamanna R, Toruner GA, Hu S, Loghavi S, Ok CY, Medeiros LJ, Tang G. Optical Genome Mapping in Myelodysplastic Syndromes. Modern Pathology 38(10), 2025. e-Pub 2025. PMID: 40780682.
10. Sameeta F, Wang W, Jelloul FZ, Nwogbo OV, Thakral B, Xu J, Li S, Ok CY, Tang G, Jia F, Medeiros LJ, Loghavi S, Jorgensen JL, Wang SA. The Significance of Detecting an Unusual Myeloblast Immunophenotype in a Presumptive Clinical Diagnosis of Myelodysplastic Syndromes. Archives of pathology & laboratory medicine 149(8):717-726, 2025. e-Pub 2025. PMID: 39711284.
11. Kaous M, Ryoo Ali HJ, Ok CY, Iliescu C, Bashoura L, Patel B, Estrov Z, Faiz S. Relapse of Acute Myelogenous Leukemia With History of Myeloproliferative Neoplasm and Exacerbation of Pulmonary Hypertension. JACC: Case Reports 30(20), 2025. e-Pub 2025. PMID: 40713114.
12. Toruner, GA, Hu, S, Loghavi, S, Ok, CY, Tang, Z, Wei, Q, Kanagal Shamanna, R, Medeiros, LJ, Tang, G. Clinical Utility of Optical Genome Mapping as an Additional Tool in a Standard Cytogenetic Workup in Hematological Malignancies. Cancers 17(9), 2025. e-Pub 2025. PMID: 40361363.
13. Tang, G, Jain, P, Hu, S, Ok, CY, Wang, WJ, Quesada, AE, Wei, Q, Li, S, Xu, J, Loghavi, S, Toruner, GA, Medeiros, LJ. Optical genome mapping reveals diverse mechanisms of cyclin activation in mantle cell lymphomas lacking IGH::CCND1. Human Pathology 159, 2025. e-Pub 2025. PMID: 40381701.
14. Kim, DH, Medeiros, LJ, Xu, J, Tang, G, Qiu, L, Wang, S, Ok, CY, Wang, W, Yin, CC, You, MJ, Garces, S, Lin, P, Li, S. Diffuse Large B-Cell Lymphoma/High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements. Modern Pathology 38(5), 2025. e-Pub 2025. PMID: 39805522.
15. Gaulin C, Jain P, Nair R, Iyer SP, Lee HJ, Fayad L, Feng L, Ok CY, Kanagal-Shamanna R, Oriabure O, Chen W, Xu G, Deswal A, Iliescu C, Badillo M, Ky M, Avellaneda M, Tangc G, Medeiros LJ, Vega F, Flowers CR, Wang ML. Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma. Leuk Lymphoma 66(5):956-960, 2025. e-Pub 2025. PMID: 39838574.
16. Wang, P, Yang, RK, Jelloul, FZ, Luthra, R, Routbort, MJ, Chen, H, Loghavi, S, Ok, CY, Kanagal Shamanna, R, Roy Chowdhuri, S, Medeiros, LJ, Patel, KP. Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 40138600.
17. Hong Fang, DW, Ok, CY, Jorgensen, JL, Medeiros, LJ, Wang, W, Wang, S. Advancing Diagnostic Accuracy and Quality of Patient Care Through the Implementation of a Flow Cytometry Quality Assurance Program. Archives of Pathology and Laboratory Medicine 149(2):e26-e30, 2025. e-Pub 2025. PMID: 38871355.
18. Dimopoulos YP, Wang W, Wang SA, Loghavi S, DiNardo CD, Gerstein Y, Hu S, Tang Z, Ilagan CJL, Thakral B, El Hussein S, Xu J, Li S, Lin P, Patel KP, Ok CY, Medeiros LJ, Fang H. The spectrum of hematologic neoplasms in patients with Li-Fraumeni syndrome. Am J Hematol 99(12):2416-2419, 2024. e-Pub 2024. PMID: 39392132.
19. Zhang JR, Wu SY, Jain P, Ok CY, Yan F, Chen W, Oriabure O, Dabaja B, Gunther J, Fang P, Pinnix C, Wang ML, Gaulin C. Characteristics, treatment, and outcomes of mantle cell lymphoma with cutaneous involvement. Leuk Lymphoma 65(11):1729-1732, 2024. e-Pub 2024. PMID: 38972062.
20. Kim DH, Jia F, Patel KP, Bose P, Wang SA, Bueso-Ramos C, Ok CY. Utility of KIT Mutations in Myeloid Neoplasms Without Documented Systemic Mastocytosis to Detect Hidden Mast Cells in Bone Marrow. Clin Lymphoma Myeloma Leuk 24(11):e878-e882, 2024. e-Pub 2024. PMID: 39107203.
21. Hu, Z, Ok, CY. Immature erythroblasts in pleural effusion. Blood 144(7):794, 2024. e-Pub 2024. PMID: 39145944.
22. El-Dana, F, Garces Narvaez, SA, El-Mallawany, NK, Agrusa, JE, Dreyer, Z, Marcogliese, A, Elghetany, MT, Punia, JN, Ok, CY, Patel, KP, Lopez-Terrada, D, Fisher, KE, Curry, CV. Childhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma. Pediatric and Developmental Pathology 27(4):348-353, 2024. e-Pub 2024. PMID: 38468555.
23. Nwogbo, OV, Fang, H, Wang, W, Xu, J, Miranda, R, Bose, P, Ok, CY, Jorgensen, JL, Medeiros, LJ, Wang, S. Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis. American journal of clinical pathology 161(6):598-608, 2024. e-Pub 2024. PMID: 38372648.
24. Kim, DH, Siddiqui, SH, Jain, P, Wang, ML, Thakral, B, Li, S, Miranda, RN, Vega Vazquez, F, Medeiros, LJ, Ok, CY. TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present. Human Pathology 146:1-7, 2024. e-Pub 2024. PMID: 38460798.
25. Quesada, AE, Hu, S, Li, S, Toruner, GA, Wei, Q, Loghavi, S, Ok, CY, Jain, P, Thakral, B, Nwogbo, OV, Kim, D, Iyer, SP, You, MJ, Medeiros, LJ, Tang, G. Optical genomic mapping is a helpful tool for detecting CCND1 rearrangements in CD5-negative small B-cell lymphoma. Human Pathology 144:71-76, 2024. e-Pub 2024. PMID: 38301962.
26. Nahmod KA, Sasaki K, Ok CY, Loghavi S. Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution. Am J Hematol 99(2):329-330, 2024. e-Pub 2024. PMID: 37243496.
27. Wang SA, Jorgensen JL, Hu S, Jia F, Li S, Loghavi S, Ok CY, Thakral B, Xu J, Medeiros LJ, Wang W. Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection. Cytometry B Clin Cytom 104(5):356-366, 2023. e-Pub 2023. PMID: 37605812.
28. Hill, H, Jain, P, Ok, CY, Sasaki, K, Chen, H, Wang, L, Chen, K. Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma. Cancer Research Communications 3(8):1435-1446, 2023. e-Pub 2023. PMID: 37538987.
29. Jelloul FZ, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, You MJ, Patel KP, Medeiros LJ, Quesada AE. DDX41 mutations in patients with non-myeloid hematologic neoplasms. Am J Hematol 98(8):E193-E196, 2023. e-Pub 2023. PMID: 37154083.
30. Khanlari M, Mo H, Kim DH, Sakhdari A, Young KH, Jain P, Wang M, Li S, Kanagal-Shamanna R, Miranda RN, Vega F, Medeiros LJ, Ok CY. Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features. Am J Surg Pathol 47(8):849-858, 2023. e-Pub 2023. PMID: 37288826.
31. Marques-Piubelli ML, Kim DH, Medeiros LJ, Lu W, Khan K, Gomez-Bolanos LI, Rodriguez S, Parra ER, Ok CY, Aradhya A, Solis LM, Nieto YL, Steiner R, Ahmed S, Vega F. CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy. Histopathology 83(1):143-148, 2023. e-Pub 2023. PMID: 36994939.
32. Shuai W, Zuo Z, Li N, Garces S, Jelloul FZ, Ok CY, Li S, Xu J, You MJ, Wang W, Rehder C, Jabbour EJ, Patel KP, Medeiros LJ, Yin CC. ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia. Cancer 129(6):878-889, 2023. e-Pub 2023. PMID: 36583229.
33. Li S, Qiu L, Xu J, Lin P, Ok CY, Tang G, McDonnell TJ, James You M, Khanlari M, Miranda RN, Jeffrey Medeiros L. High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL. Leukemia 37(2):422-432, 2023. e-Pub 2023. PMID: 36513804.
34. Zuo Z, Medeiros LJ, Garces S, Routbort MJ, Ok CY, Loghavi S, Kanagal-Shamanna R, Jelloul FZ, Garcia-Manero G, Chien KS, Patel KP, Luthra R, Yin CC. Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms. Biology (Basel) 12(1):13, 2022. e-Pub 2022. PMID: 36671709.
35. Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, El-Hussein S, Kanagal-Shamanna R, Luthra R, Hu S, Lin P, Pemmaraju N, Bose P, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol 35(11):1677-1683, 2022. e-Pub 2022. PMID: 35690645.
36. Sakhdari A, Class C, Montalban-Bravo G, Sasaki K, Bueso-Ramos CE, Patel KP, Routbort MJ, Loghavi S, Ok CY, Quesada A, Khoury JD, Konoplev SN, Kantarjian HP, Garcia-Manero G, Medeiros LJ, Kanagal-Shamanna R. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Mod Pathol 35(9):1212-1219, 2022. e-Pub 2022. PMID: 35504958.
37. Jelloul FZ, Yang R, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda W, Jain N, Thompson P, Luthra R, Medeiros LJ, Patel KP. Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res 116:106827, 2022. e-Pub 2022. PMID: 35430388.
38. Jelloul FZ, Yang RK, Wang P, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda WG, Jain N, Thompson PA, Luthra R, Medeiros LJ, Patel KP. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol 97(3):E100-E102, 2022. e-Pub 2022. PMID: 34989420.
39. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Research Group MC, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol 23(3):406-415, 2022. e-Pub 2022. PMID: 35074072.
40. El Hussein S, DiNardo CD, Takahashi K, Khoury JD, Fang H, Furudate K, Lyapichev KA, Garces S, Kanagal-Shamanna R, Ok CY, Patel KP, Routbort MJ, Ravandi F, Medeiros LJ, Wang SA, Loghavi S. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant 57(3):370-376, 2022. e-Pub 2022. PMID: 34992253.
41. Jain P, Zhao S, Lee HJ, Hill HA, Ok CY, Kanagal-Shamanna R, Hagemeister FB, Fowler N, Fayad L, Yao Y, Liu Y, Moghrabi OB, Navsaria L, Feng L, Nogueras Gonzalez GM, Xu G, Thirumurthi S, Santos D, Iliescu C, Tang G, Medeiros LJ, Vega F, Avellaneda M, Badillo M, Flowers CR, Wang L, Wang ML. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol 40(2):JCO2101797, 2022. e-Pub 2022. PMID: 34797699.
42. Qiu L, Xu J, Tang G, Wang SA, Lin P, Ok CY, Garces S, Yin CC, Khanlari M, Vega F, Medeiros LJ, Li S. Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall. Hum Pathol 119:59-68, 2022. e-Pub 2022. PMID: 34767860.
43. Tashakori M, Kim DH, Kanagal-Shamanna R, Vega F, Miranda RN, Jain P, Wang M, Medeiros LJ, Ok CY. Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases. Hum Pathol 118:60-68, 2021. e-Pub 2021. PMID: 34655612.
44. Martinez-Baquero D, Sakhdari A, Mo H, Kim DH, Kanagal-Shamanna R, Li S, Young KH, O'Malley DP, Dogan A, Jain P, Wang ML, McDonnell TJ, Miranda RN, Vega F, Medeiros LJ, Ok CY. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. Mod Pathol 34(12):2183-2191, 2021. e-Pub 2021. PMID: 34376807.
45. Evans MG, Medeiros LJ, Marques-Piubelli ML, Wang HY, Ortiz-Hidalgo C, Pina-Oviedo S, Morine A, Clemens MW, Hunt KK, Iyer S, Hu Q, Recavarren C, Demichelis R, Romero M, Sohani AR, Misialek M, Amin MB, Bueso-Ramos CE, Carballo-Zarate AA, Lee HJ, Ok CY, Xu J, Miranda RN. Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease. Mod Pathol 34(12):2148-2153, 2021. e-Pub 2021. PMID: 34155351.
46. Wang SA, Ok CY, Kim AS, Lucas F, Morgan EA, Thakral B, Patel S, Nardi V, Patel KM, Weinberg OK, Hasserjian RP. Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. Am J Hematol 96(11):E420-E423, 2021. e-Pub 2021. PMID: 34416041.
47. Weinberg OK, Chisholm KM, Ok CY, Fedoriw Y, Grzywacz B, Kurzer JH, Mason EF, Moser KA, Bhattacharya S, Xu M, Babu D, Foucar K, Tam W, Bagg A, Orazi A, George TI, Wang W, Wang SA, Arber DA, Hasserjian RP. Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Mod Pathol 34(7):1358-1366, 2021. e-Pub 2021. PMID: 33526873.
48. Augustyn A, Medeiros LJ, Ludmir EB, Gunther J, Fang P, Li S, Ok CY, Bankston ME, Verma V, Pasalic D, Ahmed S, Nastoupil LJ, Westin JR, Strati P, Neelapu SS, Nair R, Steiner RE, Iyer SP, Rodriguez A, Fayad LE, Flowers CR, Dabaja BS, Pinnix CC. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma 62(6):1-12, 2021. e-Pub 2021. PMID: 33480830.
49. Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Navsaria L, Nastoupil L, Lee HJ, Tang G, Yin CC, Badillo M, Nair R, Li S, Patel KM, Flowers C, Vega F, Wang L, Wang ML. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. American Journal of Hematology 96(5):E137-E140, 2021. e-Pub 2021. PMID: 33491779.
50. Zhang S, Jian V, Han G, Liu Y, Zhang R, McIntosh J, Wang R, Wang Y, Santo D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Zhou J, Kanagal-Shamanna R, Ok CY, Lee H, Steiner RE, Zhang J, Song X, Nair R, Ahmed S, Rodriguez A, Thirumurthy S, Jain P, Wagner-Bartak N, Hill H, Nomie K, Flowers C, Futreal A, Wang L, Wang M. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nature communications 12(1), 2021. e-Pub 2021. PMID: 34001881.
51. Fang H, Medeiros LJ, Tang Z, Wang W, Ok CY, Patel KP, Khoury JD, Thakral B. From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later. Annals of Diagnostic Pathology 50:151649, 2021. e-Pub 2021. PMID: 33189964.
52. Ok CY, Trowell KT, Parker KG, Moser K, Weinberg OK, Rogers HJ, Reichard KK, George TI, Hsi ED, Bueso-Ramos CE, Tam W, Orazi A, Bagg A, Arber DA, Hasserjian RP, Wang SA. Pathologic Spectrum of Chronic Myeloid Neoplasms Harboring Concomitant Mutations in Myeloproliferative Neoplasm Driver Genes (JAK2/MPL/CALR) and SF3B1. Modern Pathology 34(1):20-31, 2021. e-Pub 2021. PMID: 32694616.
53. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
54. Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Sasaki K, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna R. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo Acute Myeloid Leukemia with mutated RUNX1. Modern Pathology 33(9):1678-1689, 2020. e-Pub 2020. PMID: 32238878.
55. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Advances 4(6):1038-1050, 2020. e-Pub 2020. PMID: 32191807.
56. Sakhdari A, Loghavi S, Thakral B, Kanagal-Shamanna R, Yin CC, Zhuang Z, Routbort MJ, Patel KP, Luthra R, Medeiros LJ, Ok CY. RAS and TP53, not NOTCH1, Can Predict Survival in Adults with T-Cell Lymphoblastic Leukemia Treated with Hyper-CVAD. Cancer Med 9(3):849-858, 2020. e-Pub 2020. PMID: 31804006.
57. Chen Z, Ok CY, Wang W, Goswami M, Tang G, Routbort M, Jorgensen JL, Medeiros LJ, Wang SA. Low-Grade Myelodysplastic Syndromes With Preserved CD34+ B-Cell Precursors (CD34+ Hematogones). Cytometry B Clin Cytom 98(1):36-42, 2020. e-Pub 2020. PMID: 31211490.
58. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
59. Chen Z, Wang SA, Goswami M, Tang G, Routbort MJ, Patel KP, Luthra R, Medeiros LJ, Ok CY. Comparison of Therapy-Related Myelodysplastic Syndrome With Ring Sideroblasts and De Novo Myelodysplastic Syndrome With Ring Sideroblasts. Leuk Res 86:106227, 2019. e-Pub 2019. PMID: 31557598.
60. Kim DH, Medeiros LJ, Aung PP, Young KH, Miranda RN, Ok CY. Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases. Am J Surg Pathol 43(10):1421-1428, 2019. e-Pub 2019. PMID: 31219818.
61. Sakhdari A, Tang Z, Ok CY, Bueso-Ramos CE, Medeiros LJ, Huh YO. Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Cancer Genet 238:18-22, 2019. e-Pub 2019. PMID: 31425921.
62. Weinberg OK, Hasserjian RP, Baraban E, Ok CY, Geyer JT, JKSS P, Kurzer JH, Rogers HJ, Nardi V, Stone RM, Garcia JS, Hsi ED, Bagg A, Wang SA, Orazi A, Arber DA. Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol 32(9):1373-1385, 2019. e-Pub 2019. PMID: 31000771.
63. Sakhdari A, Ok CY, Patel KP, Kanagal-Shamanna R, Yin CC, Zuo Z, Hu S, Routbort MJ, Luthra R, Medeiros LJ, Khoury JD, Loghavi S. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol 41:38-42, 2019. e-Pub 2019. PMID: 31132650.
64. Khogeer H, Rahman H, Jain N, Angelova EA, Yang H, Quesada A, Ok CY, Sui D, Wei P, Al Fattani A, Pierce S, Loghavi S, Lamb A, Hu P, Thakral B, Kanagal-Shamanna R, Jorgensen JL, Jabbour EJ, Kantarjian HM, Medeiros LJ, Khoury JD. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol 186(4):538-548, 2019. e-Pub 2019. PMID: 31115909.
65. Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KP. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol 94(7):757-766, 2019. e-Pub 2019. PMID: 30963592.
66. Sakhdari A, Moghaddam PA, Ok CY, Walter O, Tomaszewicz K, Caporelli ML, Meng X, LaFemina J, Whalen G, Belkin E, Zivny J, Wassef W, Woda BA, Hutchinson LM, Cosar EF. Somatic molecular analysis augments cytologic evaluation of pancreatic cyst fluids as a diagnostic tool. Oncotarget 10(40):4026-4037, 2019. e-Pub 2019. PMID: 31258847.
67. Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
68. Tang Z, Tang G, Hu S, Patel KP, Cameron Yin C, Wang W, Lin P, Toruner GA, Ok CY, Gu J, Lu X, Khoury JD, Jeffrey Medeiros L. Data on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies. Data Brief 24:104025, 2019. e-Pub 2019. PMID: 31193989.
69. O'Malley DP, Dogan A, Fedoriw Y, Medeiros LJ, Ok CY, Salama ME. American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma. Ann Diagn Pathol 39:105-110, 2019. e-Pub 2019. PMID: 30802809.
70. Tang Z, Tang G, Hu S, Patel KP, Yin CC, Wang W, Lin P, Toruner GA, Ok CY, Gu J, Lu X, Khoury JD, Medeiros LJ. Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations. Cancer Genet 233-234:21-31, 2019. e-Pub 2019. PMID: 31109591.
71. Ok CY, Loghavi S, Sui D, Wei P, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Tang G, Tang Z, Jorgensen JL, Luthra R, Ravandi F, Kantarjian HM, DiNardo CD, Medeiros LJ, Wang SA, Patel KP. Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica 104(2):305-311, 2019. e-Pub 2019. PMID: 30171025.
72. Patel KP, Ruiz-Cordero R, Chen W, Routbort MJ, Floyd K, Rodriguez S, Galbincea J, Barkoh BA, Hatfield D, Khogeer H, Kanagal-Shamanna R, Yin CC, Zuo Z, Loghavi S, Ok CY, DiNardo CD, Luthra R, Medeiros LJ. Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48 Hours of Sample Collection. J Mol Diagn 21(1):89-98, 2019. e-Pub 2019. PMID: 30577887.
73. Ok CY, Medeiros LJ, Thakral B, Tang G, Jain N, Jabbour E, Pierce SA, Konoplev S. High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma. Mod Pathol 32(1):48-58, 2019. e-Pub 2019. PMID: 30181564.
74. Garces S, Khoury JD, Kanagal-Shamanna R, Salem A, Wang SA, Ok CY, Hu S, Patel KP, Routbort MJ, Luthra R, Tang G, Schlette EJ, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. Hum Pathol 82:215-231, 2018. e-Pub 2018. PMID: 30086334.
75. Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang ML. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol 183(4):578-587, 2018. e-Pub 2018. PMID: 30175400.
76. Mi X, Griffin G, Lee W, Patel S, Ohgami R, Ok CY, Wang S, Geyer JT, Xiao W, Roshal M, Garcia JS, Silverman LB, Sallan SE, Aster JC, Harris MH, Weinberg OK. Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations. Am J Hematol 93(11):1358-1367, 2018. e-Pub 2018. PMID: 30117174.
77. Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin CC, Kanagal-Shamanna R, Wang SA, Jorgensen JL, Medeiros LJ, Ok CY. Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. Oncotarget 9(9):8441-8449, 2018. e-Pub 2018. PMID: 29492206.
78. Wang W, Routbort MJ, Tang Z, Ok CY, Patel KP, Daver N, Garcia-Manero G, Medeiros LJ, Wang SA. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. Eur J Haematol 99(6):536-543, 2017. e-Pub 2017. PMID: 28926144.
79. Joo, JW, Konoplev, SN, McDonnell, TJ, Ok, CY. B-acute lymphoblastic leukemia/lymphoma (B-ALL) with precedent or concurrent myelodysplastic syndrome (MDS) with deletion 5q. Journal of Hematopathology 10(2):75-80, 2017. e-Pub 2017.
80. Wang W, Routbort MJ, Ok CY, Patel KP, Sun Y, Kanagal-Shamanna R, Medeiros LJ, Wang SA. Characterization of TP53 mutations in clonal cytopenia of undetermined significance. Am J Hematol 92(8):E175-E177, 2017. e-Pub 2017. PMID: 28494520.
81. Margolskee E, Hasserjian RP, Hassane D, Tam W, Mathew S, Ok CY, Wang SA, Oak J, Arber DA, Orazi A. Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. Am J Clin Pathol 148(1):49-57, 2017. e-Pub 2017. PMID: 28927162.
82. Cai Q, Tu M, Xu-Monette ZY, Sun R, Manyam GC, Xu X, Tzankov A, Hsi ED, Møller MB, Medeiros LJ, Ok CY, Young KH. NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Mod Pathol 30(6):854-876, 2017. e-Pub 2017. PMID: 28281555.
83. Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, Bhagat G, Zhang S, Pasqualucci L, Zhang L, Visco C, Dybkaer K, Chiu A, Orazi A, Zu Y, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Westin J, Fowler N, Miranda RN, Ok CY, Li J, Medeiros LJ, Young KH. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis for activated B-cell-like diffuse large B-cell lymphoma. Leukemia 31(3):625-636, 2017. e-Pub 2017. PMID: 27568520.
84. Loghavi S, Bueso-Ramos CE, Kanagal-Shamanna R, Ok CY, Salim AA, Routbort MJ, Mehrotra M, Verstovsek S, Medeiros LJ, Luthra R, Patel KP. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. Am J Clin Pathol 145(3):418-27, 2016. e-Pub 2016. PMID: 27124925.
85. Jain P, Ok CY, Konoplev S, Patel KP, Jorgensen J, Estrov Z, Luthra R, Kantarjian H, Ravandi F. Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?. J Clin Oncol 34(7), 2016. e-Pub 2016. PMID: 24982452.
86. Ok CY, Leventaki V, Wang SA, Dinardo C, Medeiros LJ, Konoplev S. Detection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy. Am J Clin Pathol 145(2):271-6, 2016. e-Pub 2016. PMID: 26800764.
87. Ohanian M, Bueso-Ramos C, Ok CY, Lin P, Patel K, Alattar ML, Khoury JD, Rozovski U, Estrov Z, Huh YO, Cortes J, Abruzzo LV. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer Genet 208(11):571-4, 2015. e-Pub 2015. PMID: 26382622.
88. Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HM, McDonnell TJ, Ok CY, Kantarjian HM, Medeiros LJ, Hu S. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood 126(14):1699-706, 2015. e-Pub 2015. PMID: 26243778.
89. Yabe M, Medeiros LJ, Wang SA, Konoplev S, Ok CY, Loghavi S, Lu G, Flores L, Khoury JD, Cason RC, Young KH, Miranda RN. Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of γδ T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With γδ T-Cell Large Granular Lymphocytic Leukemia. Am J Clin Pathol 144(4):607-19, 2015. e-Pub 2015. PMID: 26386082.
90. Li L, Xu-Monette ZY, Ok CY, Tzankov A, Manyam GC, Sun R, Visco C, Zhang M, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Wang J, Parsons BM, Winter JN, Piris MA, Pham LV, Medeiros LJ, Young KH. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget 6(27):23157-80, 2015. e-Pub 2015. PMID: 26324762.
91. Ok CY, Xu-Monette ZY, Li L, Manyam GC, Montes-Moreno S, Tzankov A, Visco C, Dybkær K, Routbort MJ, Zhang L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Rao H, Møller MB, Winter JN, Piris MA, Wang SA, Medeiros LJ, Young KH. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Mod Pathol 28(9):1202-13, 2015. e-Pub 2015. PMID: 26111978.
92. Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?. Oncotarget 6(16):13933-45, 2015. e-Pub 2015. PMID: 26101854.
93. Cleven AH, Nardi V, Ok CY, Goswami M, Dal Cin P, Zheng Z, Iafrate AJ, Abdul Hamid MA, Wang SA, Hasserjian RP. High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Mod Pathol 28(4):552-63, 2015. e-Pub 2015. PMID: 25412846.
94. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Fu B, Tang G, Goswami M, Singh R, Kanagal-Shamanna R, Pierce SA, Young KH, Kantarjian HM, Medeiros LJ, Luthra R, Wang SA. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res 39(3):348-54, 2015. e-Pub 2015. PMID: 25573287.
95. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, Goswami M, Young KH, Singh R, Medeiros LJ, Kantarjian HM, Luthra R, Wang SA. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol 8:45, 2015. e-Pub 2015. PMID: 25952993.
96. Ok CY, Chen J, Xu-Monette ZY, Tzankov A, Manyam GC, Li L, Visco C, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Zhao X, Ponzoni M, Ferreri AJ, Bertoni F, Farnen JP, Møller MB, Piris MA, Winter JN, Medeiros LJ, Young KH. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res 20(19):5113-23, 2014. e-Pub 2014. PMID: 25124685.
97. Ok CY, Wang SA, Amin HM. Leukemic phase of ALK(+) anaplastic large-cell lymphoma, small-cell variant: clinicopathologic pitfalls of a rare entity. Clin Lymphoma Myeloma Leuk 14(4):e123-6, 2014. e-Pub 2014. PMID: 24685107.
98. Ok CY, Xu-Monette ZY, Tzankov A, O'Malley DP, Montes-Moreno S, Visco C, Møller MB, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Han van Krieken J, Ponzoni M, Farnen JP, Piris MA, Winter JN, Medeiros LJ, Young KH. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer 120(12):1818-1829, 2014. e-Pub 2014. PMID: 24648050.
99. Ok CY, Yin CC, Yabe M, Bueso-Ramos CE, Miranda RN, Medeiros LJ, Konoplev SN. Lymphoma with features intermediate between aggressive T-large granular lymphocytic leukemia and hepatosplenic T-cell lymphoma: a diagnostic dilemma?. Clin Lymphoma Myeloma Leuk 14(3):e95-e100, 2014. e-Pub 2014. PMID: 24524924.
100. Strati P, Manning JT, Ok CY, Garcia-Manero G, Estrov Z. Interaction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia. Leuk Lymphoma 55(6):1425-7, 2014. e-Pub 2014. PMID: 23987820.
101. Ok CY, Li L, Xu-Monette ZY, Visco C, Tzankov A, Manyam GC, Montes-Moreno S, Dybkaer K, Dybaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Chen J, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ai W, Ponzoni M, Ferreri AJ, Farnen JP, Møller MB, Bueso-Ramos CE, Miranda RN, Winter JN, Piris MA, Medeiros LJ, Young KH. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res 20(9):2338-2349, 2014. e-Pub 2014. PMID: 24583797.
102. Ok CY, Hasserjian RP, Foz PS, Stinhgo F, Zuo Z, Young KH, Patel IK, Medeiros LJ, Garcia-Manero G, Wang SA. Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia 28(1):185-189, 2014. e-Pub 2014. PMID: 23787392.
103. Fu B, Ok CY, Goswami M, Xei W, Jaso JM, Muzzafar T, Bueso-Ramos C, Verstovsek S, Garcia-Manero G, Medeiros LJ, Wang SA. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Ann Hematol 92(10):1335-43, 2013. e-Pub 2013. PMID: 23660629.
104. Yu H, Ok CY, Hesse A, Nordell P, Connor D, Sjostedt E, Pechet L, Snyder LM. Evaluation of an automated digital imaging system, Nextslide Digital Review Network, for examination of peripheral blood smears. Arch Pathol Lab Med 136(6):660-7, 2012. e-Pub 2012. PMID: 22646275.
105. Ok CY, Akalin A. Gastric heterotopia in the rectum. Journal of Medical Cases 3(2):113-115, 2012. e-Pub 2012.
106. Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC, Garcia-Manero G, Wang SA, Hasserjian RP. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol 30(19):2340-7, 2012. e-Pub 2012. PMID: 22585703.
107. Ok CY, Medeiros LJ, Hu Y, Bueso-Ramos CE, Wang SA. Transient/reversible ring sideroblasts in bone marrow of patients post cytotoxic therapies for primary malignancies. Leuk Res 35(12):1605-10, 2011. e-Pub 2011. PMID: 21596435.
108. Hao S, Smith TW, Chu PG, Liu Q, Ok CY, Woda BA, Lu D, Lin P, Wang SA, Dresser K, Rock KL, Jiang Z. The oncofetal protein IMP3: a novel molecular marker to predict aggressive meningioma. Arch Pathol Lab Med 135(8):1032-6, 2011. e-Pub 2011. PMID: 21809995.

Invited Articles

1. Ok, CY, Medeiros, LJ. Cyclin D1-negative mantle cell lymphoma. Human Pathology 156, 2025. e-Pub 2025. PMID: 39571691.
2. Ok CY, Medeiros LJ. High-Grade B-cell Lymphoma: A Term Re-purposed in the Revised WHO Classification. Pathology 52(1):68-77, 2020. e-Pub 2020. PMID: 31735344.
3. Ok CY, Li L, Young KH. EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management. Exp Mol Med 47(1):e132, 2015. e-Pub 2015. PMID: 25613729.

Review Articles

1. Marques-Piubelli ML, Lyapichev KA, Fnu A, Adrada B, Stewart J, Hunt KK, Clemens MW, Iyer S, Wu Y, El Hussein S, Xu J, Ok CY, Li S, Pierson DM, Ferrufino-Schmidt MC, Nahmod KA, Yoga A, Hunsicker L, Evans MG, Resetkova E, Qiu L, Khanlari M, Garces SA, Bueso-Ramos CE, Medeiros LJ, Miranda RN. The Spectrum of Non-neoplastic Changes Associated With Breast Implants. Am J Surg Pathol 48(6):e43-e64, 2024. e-Pub 2024. PMID: 38451836.
2. Siddiqui SH, Thakral B, Aakash F, Ok CY, Tang Z, Medeiros L. From the archives of MD Anderson Cancer Center: Sporadic Burkitt lymphoma with a complex karyotype and SOX11 expression. Ann Diagn Pathol 66:152182, 2023. e-Pub 2023. PMID: 37543028.
3. Ok CY, Young KH. Checkpoint inhibitors in hematological malignancies. J Hematol Oncol 10(1):103, 2017. e-Pub 2017. PMID: 28482851.
4. Ok CY, Young KH. Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treat Rev 54:99-109, 2017. e-Pub 2017. PMID: 28242522.
5. Ok CY, Papathomas TG, Medeiros LJ, Young KH. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood 122(3):328-40, 2013. e-Pub 2013. PMID: 23649469.
6. Ok CY, Singh RR, Vega F. Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms. Am J Pathol 180(1):2-11, 2012. e-Pub 2012. PMID: 22056910.

Professional Educational Materials

1. Khanlari M, Ok CY. Mantle cell lymphoma-Classic. PathologyOutlines.com, 2020.
2. Khanlari M, Ok CY. Mantle cell lymphoma-Aggressive variants. PathologyOutlines.com, 2020.
3. Parisi X, Ok CY. Mantle cell lymphoma-Classic. PathologyOutlines.com.
4. Parisi X, Ok CY. Mantle cell lymphoma-aggressive. PathologyOutlines.com.

Editorials

1. Ok CY, Young KH. Age cutoff in lymphoma diagnosis. Aging (Albany NY) 7(7):451-2, 2015. PMID: 26187891.

Abstracts

1. Ok CY, Sa W. Case #271. Society for Hematopathology/European Association for Haematopathology 2025 Workshop, 2025. e-Pub 2025.
2. OK CY, Reichard KK, Patnaik M, Natu A, Daneshpajouhnejad P, Fathalla LA, Symes E, Barone P, Geyer JT, Foucar KK, Bueso-Ramos C, Bagg A, Hasserjian R, Orazi A, Arber DA, Wang SA. Chronic myelomonocytic leukemia in younger patients demonstrates different clinical and molecular genetic features. The United States and Canadian Academy of Pathology Annual Meeting, 2025. e-Pub 2025.
3. Nwogbo OV, Li S, Miranda RN, Vega F, Medeiros LJ, Ok CY. TP53-Mutated Mantle Cell Lymphoma shows Distinct Mutational Profiles from TP53-Wild Type Mantle Cell Lymphoma. The United States and Canadian Academy of Pathology Annual Meeting, 2024. e-Pub 2024.
4. Ok CY, Hu S. Case #136. Society for Hematopathology/European Association for Haematopathology 2023 Workshop, 2023. e-Pub 2023.
5. Kim DH, Jelloul FZ, Loghavi S, Kanagal-Shamanna R, Yin CC, Zuo Z, Patel KP, Routbort M, Li S, Vega F, Miranda RN, Medeiros LJ, Ok CY. Next-Generation Sequencing Identifies Approximately One Third of Mantle Cell Lymphoma Patients with Nuclear Factor-kappa B Pathway Mutations. The United States and Canadian Academy of Pathology Annual Meeting, 2023. e-Pub 2023.
6. Kim DH, Jia F, Ok CY. Utility of KIT p.D816 in myeloid neoplasm without documented systemic mastocytosis to detect hidden mast cells in bone marrow. The European Hematology Association Hybrid Congress, 2022. e-Pub 2022.
7. Kim DH, Li S, Kanagal-Shamanna R, Miranda RN, Vega F, Medeiros LJ, Ok CY. Next-generation Sequencing Revealed Frequent TP53 mutation in Mantle Cell Lymphoma with Enhancer of Zeste Homolog 2 (EZH2) Expression. The United States and Canadian Academy of Pathology Annual Meeting,, 2022. e-Pub 2022.
8. OK CY, Trowell KT, Parker KG, Moser K, Weinberg OK, Rogers HJ, Reichard KK, George TI, Hsi ED, Bueso-Ramos CE, Tam W, Orazi A, Bagg A, Arber DA, Hasserjian RP, Wang SA. Pathologic Spectrum of Chronic Myeloid Neoplasms Harboring Concomitant Mutations in Myeloproliferative Neoplasm Driver Genes (JAK2/MPL/CALR) and SF3B1. The United States and Canadian Academy of Pathology Annual Meeting, 2020. e-Pub 2020.
9. OK CY, Trowell KT, Parker KG, Moser K, Weinberg OK, Rogers HJ, Reichard KK, George TI, Hsi ED, Bueso-Ramos CE, Tam W, Orazi A, Bagg A, Arber DA, Hasserjian RP, Wang SA. Pathologic Spectrum of Chronic Myeloid Neoplasms Harboring Concomitant Mutations in Myeloproliferative Neoplasm Driver Genes (JAK2/MPL/CALR) and SF3B1. The United States and Canadian Academy of Pathology Annual Meeting, 2020. e-Pub 2020.
10. Xie W, Sakhdari A, Loghavi S, Kanagal-Shamanna R, Zuo Z, Yin CC, Routbort MJ, Patel KP, Luthra R, Medeiros LJ, Ok CY. The Result of 122 Consecutive NGS-based Analysis of T-Lymphoblastic Leukemia/Lymphoma and Early T-cell Precursor Leukemia. The Association of Molecular Pathology Annual Meeting, 2019. e-Pub 2019.
11. Xie W, Sakhdari A, Loghavi S, Kanagal-Shamanna R, Zuo Z, Yin CC, Routbort MJ, Patel KP, Luthra R, Medeiros LJ, Ok CY. The Result of 122 Consecutive NGS-based Analysis of T-Lymphoblastic Leukemia/Lymphoma and Early T-cell Precursor Leukemia. The Association of Molecular Pathology Annual Meeting, 2019. e-Pub 2019.
12. Sakhdari A, Young KH, Miranda RN, Medeiros LJ, Ok CY. Enhancer of Zeste Homolog 2 (EZH2) Expression in Mantle Cell Lymphoma Correlates with Ki-67 Proliferation Rate, but Does Not Correlate with Trimethylation of Histone H3 at Lysine 27. The United States and Canadian Academy of Pathology Annual Meeting, 2019. e-Pub 2019.
13. OK CY, Chen Z, Loghavi S, Kanagal-Shamanna R, Zhuang Z, Yin CC, Routbort M, Patel KP, Luthra R Medeiros LJ, Wang SA. Prevalence and Clinical Implications of Splicing Factor Gene Mutation in Patients with Primary Myelofibrosis. The United States and Canadian Academy of Pathology Annual Meeting, 2019. e-Pub 2019.
14. Sakhdari A, Young KH, Miranda RN, Medeiros LJ, Ok CY. Enhancer of Zeste Homolog 2 (EZH2) Expression in Mantle Cell Lymphoma Correlates with Ki-67 Proliferation Rate, but Does Not Correlate with Trimethylation of Histone H3 at Lysine 27. The United States and Canadian Academy of Pathology Annual Meeting, 2019. e-Pub 2019.
15. OK CY, Chen Z, Loghavi S, Kanagal-Shamanna R, Zho Z, Yin CC, Routbort M, Patel KP, Luthra R Medeiros LJ, Wang SA. Prevalence and Clinical Implications of Splicing Factor Gene Mutation in Patients with Primary Myelofibrosis. The United States and Canadian Academy of Pathology Annual Meeting, 2019. e-Pub 2019.
16. Sakhdari A, Loghavi S, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort M, Patel KP, Luthra R, Medeiros LJ, Ok CY. RAS and TP53, Not NOTCH1, Can Predict Survival in Adults with Acute T-Cell Lymphoblastic Leukemia Treated with HyperCVAD. BLOOD-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. e-Pub 2018.
17. Ruiz-Cordero R, Floyd K, Loghavi S, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Luthra R, Kantarjian HM, Medeiros LJ, Patel KP, Ok CY. PTPN11 Mutation is Uncommon in Acute Myeloid Leukemia, but Associated with a Complex Karyotype, Co-mutations in KRAS or NRAS and Poor Prognosis. Journal of Molecular Diagnostics 20(6):930-931, 2018. e-Pub 2018.
18. Ruiz-Cordero R, Floyd K, Loghavi S, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Luthra R, Kantarjian HM, Medeiros LJ, Patel KP, Ok CY. PTPN11 Mutation is Uncommon in Acute Myeloid Leukemia, but Associated with a Complex Karyotype, Co-mutations in KRAS or NRAS and Poor Prognosis. The Association of Molecular Pathology Annual Meeting, 2018. e-Pub 2018.
19. Weinberg OK, Hasserjian RP, Baraban, Ok CY, Geyer, Philip, Kurzer, Rogers, Nardi, Stone, Garcia, Hsi, Bagg, Wang, Orazi, Arber. Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group. BLOOD-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. e-Pub 2018.
20. Jain P, Kanagal-Shamanna R, Zhang SJ, Ok CY, Ahmed M, Nava D, Badillo M, Nomie K, Patel K, Lee HJ, Hagemeister FB, Fayad L, Nastoupil LJ, Medeiros LJ, Neelapu SS, Romaguera JE, Fowler NH, Wang LH, Wang M. Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. e-Pub 2018.
21. Ahmed M, Guo H, Zhang S, Sehgal L, Jain P, Kanagal-Shamanna R, Ok CY, Leeming A, Yao Y, Zhang L, Nomie K, Wang L, Wang M. Unravelling the Heterogeneity of Mantle Cell Lymphoma Ecosystem By Single Cell RNA Sequencing. Blood-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. e-Pub 2018.
22. Jain P, Kanagal-Shamanna R, Zhang SJ, Ok CY, Gonzalez GMN, Ahmed M, Omarya GP, Ghorab A, Boddu PC, Chen W, Lee HJ, Badillo M, Nomie K, Fayad L, Nastoupil LJ, Champlin RE, Neelapu SS, Patel K, Medeiros LJ, Romaguera JE, Fowler NH, Wang LH, Wang M. Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients. BLOOD-60th Annual Meeting of the American-Society-of-Hematology (ASH) 132(Supplement 1), 2018. e-Pub 2018.
23. Sakhdari A, Routbort M, Bueso-Ramos C, Patel K, Luthra R, Ok CY, Loghavi S, Zuo Z, Yin CC, Khoury J, Medeiros LJ, Kanagal-Shamanna R. Myelodysplastic Syndromes with EZH2 Mutations Frequently Show Multilineage Dysplasia, Chromosome 7 Alterations and Concomitant Mutations in ASXL1, RUNX1 and TET2. Modern Pathology-107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 31(Supplement 2):549-550, 2018. e-Pub 2018.
24. Thakral B, Muzzafar T, Badar I, Wang S, Miranda R, Lin P, Khoury J, Routbort M, Kanagal-Shamanna R, Loghavi S, Ok CY, Yin CC, Zuo Z, Verstovsek S, Benton C, Luthra R, Bueso-Ramos C, Medeiros LJ, Patel K. Clinicopathologic and Molecular Characteristics of Myeloid Neoplasms with Non-Canonical MPL Mutations. Laboratory Investigation-106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 98(Supplement 1):559-560, 2018. e-Pub 2018.
25. Ruiz-Cordero R, Hidalgo-Lopez JE, Bueso-Ramos C, Routbort M, Kanagal-Shamanna R, Zuo Z, Yin CC, Loghavi S, Ok CY, Jorgensen J, Wang S, Tang GL, Luthra R, Medeiros LJ, Patel K. Distinct Genetic Features of Myelodysplastic Syndromes as Defined in the Revised 2016 World Health Organization Classification. Modern Pathology-107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 31(Supplement 2):549-549, 2018. e-Pub 2018.
26. Sakhdari A, Patel K, Ok CY, Kanagal-Shamanna R, Yin CC, Zuo Z, Hu SM, Routbort M, Luthra R, Medeiros LJ, Khoury J, Loghavi S. TP53 Mutations are Common in Mantle Cell Lymphoma, Including the Indolent Leukemic Non-Nodal Variant. Modern Pathology-107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 31(Supplement 2):549-549, 2018. e-Pub 2018.
27. Quesada AE, DiNardo C, Routbort M, Bueso-Ramos C, Kanagal-Shamanna R, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang S, Benton C, Kantarjian HM, Luthra R, Medeiros LJ, Patel K. DDX41 Mutations in Myeloid Neoplasms Are Associated with Male Predominance, TP53 mutation and a High Risk of Progression to AML. Modern Pathology 31(Supplement 2):545-545, 2018. e-Pub 2018.
28. Ok CY, Singh R, Luthra R, Hatfield D, Floyd K, Loghavi S, Kanagal-Shamanna R, Zuo Z, Yin CC, Routbort M, Kantarjian HM, Medeiros LJ, Patel KP. Endleukemia Assay v1: Enabling NGS-Based Comprehensive Routine Molecular Profiling of Leukemias in Routine Clinical Care. Blood-59th Annual Meeting of the American Society of Hematology (ASH) 130(Supplement 1), 2017. e-Pub 2017.
29. Hu BY, Patel K, Wang XM, Chen HC, Thompson PA, Keating MJ, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Luthra R, Routbort M, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Wierda WG. Standardized Targeted Sequencing of 29 Genes with Recurrent Mutations in Chronic Lymphocytic Leukemia (CLL) Helps to Better Define Clinical Correlates and Genomic Hotspots. Blood-59th Annual Meeting of the American Society of Hematology (ASH) 130(Supplement 1), 2017. e-Pub 2017.
30. Romaguera JE, Lee HJ, Tarapore R, Prabhu VV, Allen JE, Schalop L, Zloza A, Ok CY, Badillo M, Wang M. Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment. Blood-59th Annual Meeting of the American-Society-of-Hematology (ASH) 130(Supplement 1), 2017. e-Pub 2017.
31. Ruiz-Cordero R, Chen W, Floyd KC, Rodriguez S, Galbincea J, Barkoh B, Routbort M, Luthra R, Singh R, Hatfield D, Kanagal-Shamanna R, Yin CC, Zuo Z, Loghavi S, Ok CY, Medeiros J, Patel KP. Breaking the Turnaround Time Barrier in Next Generation Sequencing Based Clinical Mutation Profiling Using an Integrated Workflow and Informatics Approach. Journal of Molecular Diagnostics-Annual Meeting of the Association for Molecular Pathology (AMP) 19(6):997-998, 2017. e-Pub 2017.
32. Kanagal-Shamanna R, Luthra R, Routbort MJ, Singh R, Floyd K, Abraham R, Hai S, Yin C, Zuo Z, Ok CY, Loghavi S, Medeiros L, Patel KP. Multi-Platform-Based Comprehensive Molecular Analysis of Hematological Malignancies for Somatic Mutations, Copy Number Changes and Translocations for Routine Clinical Testing. Journal of Molecular Diagnostics-Annual Meeting of the Association for Molecular Pathology (AMP) 19(6):964-964, 2017. e-Pub 2017.
33. Wang W, Routbort MJ, Ok CY, Patel KP, Luthra R, Medeiros LJ, Wang S. TP53 Mutations with a Normal Karyotype in Myelodysplastic Syndromes and Cytopenia(s) of Unknown Significance. Laboratory Investigation-106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 97(Supplement 1):384A-384A, 2017. e-Pub 2017.
34. Quesada AE, Huang RSP, Luthra R, Patel KP, Hodges K, Ok CY, Routbort MJ, Bueso-Ramos CE, Medeiros LJ, Kanagal-Shamanna R. Genetic Landscape of Non-R882 DNMT3A Mutations Is Distinct from DNMT3A R882 Mutations. Laboratory Investigation- 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 97(Supplement 1):371A-371A, 2017. e-Pub 2017.
35. Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin C, Kanagal-Shamana R, Wang SA, Jorgensen JL, Medeiros L, Ok CY. Mixed Phenotype Acute Leukemia Contains Heterogeneous Genetic Mutations by Next-Generation Sequencing. Journal of Molecular Diagnostics-Annual Meeting of the Association for Molecular Pathology (AMP) 18(6):961-961, 2016. e-Pub 2016.
36. Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin CC, Kanagal-Shamanna R, Wang SA, Jorgensen JL, Medeiros LJ, OK CY. Mixed Phenotype Acute Leukemia Contains Heterogeneous Genetic Mutations by Next-Generation Sequencing. The Association of Molecular Pathology Annual Meeting, 2016. e-Pub 2016.
37. Almohammedsalim AA, Luthra R, Ok CY, Loghavi S, Mehrotra M, Abraham R, Harmon M, Lu X, Medeiros LJ, Patel KP, Kanagal-Shamanna R. Single Nucleotide Polymorphism-Array-Based Comparative Genomic Hybridization Analysis of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Study of 168 Cases with Comparison to Traditional Genetic Testing Methods. Journal of Molecular Diagnostics-Annual Meeting of the Association for Molecular Pathology (AMP) 17(6):773-773, 2015. e-Pub 2015.
38. OK CY Salim AA, Loghavi S, Luthra R, Routbort MJ, Singh RR, Zuo Z, Medeiros LJ, Patel KP. Solving a 10-year old enigma with next generation sequencing-based assay. The Association of Molecular Pathology Annual Meeting, November 5-7, 2015, Austin, TX, USA, 2015. e-Pub 2015.
39. OK CY, Loghavi S, Salim AA, Chen H, Kanagal-Shamanna R, Chowdhuri SR, Broaddus RR, Lazar AJ, Rashid A, Manekia JH, Barkoh BA, Medeiros LJ, Singh RR, Routbort MJ, Luthra R, Patel KP. To confirm and not to confirm, that is the question for equivocal NGS findings. The Association of Molecular Pathology Annual Meeting, November 5-7, 2015, Austin, TX, USA, 2015. e-Pub 2015.
40. OK CY, Yang H, Villarreal J, Barkoh BA, Routbort MJ, Singh RR, Mantha GS, Lu H, Medeiros LJ, Luthra R, Patel KP. Development of a decision support system for specimen accessioning and uniform triaging of oncologic molecular testing. The Association of Molecular Pathology Annual Meeting, November 5-7, 2015, Austin, TX, USA, 2015. e-Pub 2015.
41. OK CY, Salim AA, Loghavi S, Luthra R, Routbort MJ, Singh RR, Zuo Z, Medeiros LJ, Patel KP. Solving a 10-year old enigma with next generation sequencing-based assay. The Association of Molecular Pathology Annual Meeting, 2015. e-Pub 2015.
42. OK CY, Loghavi S, Salim AA, Chen H, Kanagal-Shamanna R, Chowdhuri SR, Broaddus RR, Lazar AJ, Rashid A, Manekia JH, Barkoh BA, Medeiros LJ, Singh RR, Routbort MJ, Luthra R, Patel KP. To confirm and not to confirm, that is the question for equivocal NGS findings. The Association of Molecular Pathology Annual Meeting, 2015. e-Pub 2015.
43. OK CY, Yang H, Villarreal J, Barkoh BA, Routbort MJ, Singh RR, Mantha GS, Lu H, Medeiros LJ, Luthra R, Patel KP. Development of a decision support system for specimen accessioning and uniform triaging of oncologic molecular testing. The Association of Molecular Pathology Annual Meeting, 2015. e-Pub 2015.
44. Li L, Xu-Monette ZY, Ok CY, Manyam GC, Visco C, Tzankov A, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu YL, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Farnen JP, Moller MB, Piris MA, Winter JN, Medeiros LJ, Young KH. Nuclear coexpression of NF-kappa B subunit c-Rel and p53 mutants confers significantly poor survival in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A Report from the International DLBCL Rituximab-CHOP Consortium. Clinical Lymphoma Myeloma & Leukemia-20th International Hematologic Malignancies 2014 Conference 15(Supplement 1):S224-S224, 2015. e-Pub 2015.
45. Ok CY, Salim A, Loghavi S, Luthra R, Routbort M, Singh R, Zuo Z, Pierce S, Garcia-Manero G, Kantarjian H, Cortes J, Ravandi F, Andreef M, Medeiros LJ, Patel K. DNMT3A mutation as a predictive marker for relapse in acute myeloid leukemia. Modern Pathology-104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 28(Supplement 2):370A, 2015. e-Pub 2015.
46. Sakhdari A, Moghaddam PA, Ok CY, Toniaszewicz K, Cosar E, Hutchinson L. NGS Sequencing Augments Cytologic Evaluation of Pancreatic Cyst Fluids. Modern Pathology-104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 28(Supplement 2):447A, 2015. e-Pub 2015.
47. Loghavi S, Kanagal-Shamanna R, Ok CY, Almohammedsalim A, Bueso-Ramos C, Routbort M, Mehrotra M, Verstovsek S, Kantarjian H, Medeiros LJ, Luthra R, Patel K. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Megakaryocytic Features and Increased Vascular Proliferation. Modern Pathology-104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 28(Supplement 2):361A, 2015. e-Pub 2015.
48. Loghavi S, Broaddus R, Daniels M, Meric-Bernstam F, Chen K, Strong L, Almohammedsalim A, Ok CY, Brusco L, Kopetz, S, Lu, K, Lee, J, Medeiros LJ, Singh R, Patel K, Luthra R, Routbort M. Dealing With the Incidental: Experiences Implementing the ACMG Guidelines for Reporting Germline Findings in a Comprehensive Somatic Mutation Assay. Modern Pathology-104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 28(Supplement 2):460A, 2015. e-Pub 2015.
49. Ok CY, Xu-Monette ZY, Tzankov A, Visco C, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJM, Farnen JP, Møller MB, Winter JN, Piris MA, Medeiros LJ, Young KH. Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma. ASH, 2014. e-Pub 2014. PMID: 25124685.
50. Ok CY, Salim AA, Luthra R, Routbort MJ, Singh RR, Zuo Z, Kantarjian HM, Cortes JE, Ravandi F, Andreef M, Medeiros LJ, Patel KP. Next Generation Sequencing-based Monitoring for Minimal Residual Disease in Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia-20th International Hematologic Malignancies 2014 Conference 15(Supplement 1):S196-S196, 2014. e-Pub 2014.
51. Ok CY, Tzankov A, Orazi A, Bhagat G, Hsi ED, Ponzoni M, Møller MB, Piris MA, Medeiros LJ, Young KH. Immunohistochemical profiling of NF-κB subunit components in diffuse large B-cell lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study. USCAP, 2014. e-Pub 2014.
52. Ok CY, Tzankov A, Orazi A, Bhagat G, Hsi ED, Ponzoni M, Moller MB, Piris MA, Medeiros LJ, Young KH. Single Nucleotide Variation (SNV) of PRDM1 and Clinical Impact in De Novo Diffuse Large B Cell Lymphoma. Laboratory Investigation-103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 94(Supplement 1):368A, 2014. e-Pub 2014.
53. Ok CY, Tzankov A, Orazi A, Bhagat G, Hsi ED, Ponzoni M, Møller MB, Piris MA, Medeiros LJ, Young KH. Immunohistochemical profiling of NF-κB subunit components in diffuse large B-cell lymphoma. The United States and Canadian Academy of Pathology Annual Meeting, 2014. e-Pub 2014.
54. Ok CY, Patel KP, Wang SA, Routbort MJ, Fu B, Singh R, Kanagal-Shamanna R, LJ, Luthra R. Multigene Mutational Analysis Using Next Generation Sequencing (NGS) of 484 Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Laboratory Investigation-103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 94(Supplement 1):367A, 2014. e-Pub 2014.
55. Goswami RS, Ok CY, Patel KP, Wang SA, Routbort MJ, Manekia JH, Jabbar KJ, Barkoh BA, Medeiros LJ, Singh RR, Luthra R. Novel Mutations inTherapy-Related and De Novo Myelodysplasia: Results from a Next-Generation Sequencing Pilot Study. Laboratory Investigation-103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 94(Supplement 1):461A, 2014. e-Pub 2014.
56. Ok CY, Xu-Monette ZY, Tzankov A, Visco C, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJM, Farnen JP, Møller MB, Winter JN, Piris MA, Medeiros LJ, Young KH. STAT3 expressions and clinical implications in de novo diffuse large B-cell lymphoma. The American Society of Hematology Annual Meeting and Exposition, 2013. e-Pub 2013.
57. Ok CY, Huh YO. Case #84. Society for Hematopathology/European Association for Haematopathology 2013 Workshop, 2013. e-Pub 2013.
58. Ok CY, Huh YO. Case #309. Society for Hematopathology/European Association for Haematopathology 2013 Workshop, 2013. e-Pub 2013.
59. Ok CY, Wang SA. Case #83. Society for Hematopathology/European Association for Haematopathology 2013 Workshop, 2013. e-Pub 2013.
60. Ok CY, Xu-Monette ZY, Visco C, Tzankov A, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ai W, Ponzoni M, Ferreri AJM, Farnen JP, Møller MB, Bueso-Ramos CE, Winter JN, Piris MA, Medeiros LJ, Young KH. Prevalence and Clinical Implications of Epstein-Barr Virus Infection in de novo Diffuse Large B-Cell Lymphoma in Western Countries. Clinical Lymphoma Myeloma & Leukemia-9th International Hematologic Malignancies 2013 Conference 14(Supplement 3):S144-S145, 2013. e-Pub 2013.
61. Ok CY, Zuo Z, Garcia-Manero G, Medeiros LJ, Wang SA. Implications of Using the Revised International Prognostic Scoring System (IPSS-R) For Patients with Therapy-related Neoplasms. Laboratory Investigation-102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 93(Supplement 1):354A, 2013. e-Pub 2013.
62. Ok CY, Wang SA, Lin P, Medeiros LJ, Jorgensen JL. Mixed phenotype acute leukemia: experience in a single institution. USCAP 19, 2013. e-Pub 2013.
63. Zhang L, Xie W, Ok CY, Medeiros LJ, Wang SA. Myeloproliferative Neoplasms Occurring in Patients with a Cancer History. Laboratory Investigation-102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 93(Supplement 1):370A, 2013. e-Pub 2013.
64. Ok CY, Huh YO. Case #84, 2013. e-Pub 2013.
65. Ok CY, Wang SA. Case #83, 2013. e-Pub 2013.
66. Ok CY, Huh YO. Case #309, 2013. e-Pub 2013.
67. Ok CY, Wang SA, Lin P, Medeiros LJ, Jorgensen JL. Mixed phenotype acute leukemia: experience in a single institution. The United States and Canadian Academy of Pathology Annual Meeting, 2012. e-Pub 2012.
68. Ok CY, Welch M, Tomaszewicz K, Hutchinson L, Cosar EF. KRAS mutations in lipomas, atypical lipomatous tumors/well-differentiated liposarcomas (ALT) and dedifferentiated liposarcoma (DDLS). Laboratory Investigation-101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 92(Supplement 1):18A, 2012. e-Pub 2012.
69. Zhou Y, Tang G, Ok CY, Medeiros LJ, Wierda W, Wang SA. Therapy-Related Myeloid Neoplasms (t-MN) in Chronic Lymphocytic Leukemia Patients Treated with the FCR Chemotherapy Regimen. Laboratory Investigation-100th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 91(Supplement 1):334A, 2011. e-Pub 2011.
70. Ok CY, Zhou Y, Hu Y, Medeiros LJ, Wang SA. Ring sideroblasts and a normal karyotype in bone marrow of patients treated for primary malignancies and developed cytopenia. Modern Pathology-101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) 25(Supplement 2):358A, 2011. e-Pub 2011.
71. Ok CY, Walter O, Hutchinson L, Belkin E, Wassef W, Woda B, Cosar E. KRAS mutation analysis is a good adjunct to cytologic evaluation of pancreatic cyst fluids, 2011. e-Pub 2011.
72. Ok CY, Yu H, Hesse A, Nordell P, Connor D, Sjostedt E, Pechet L, Snyder LM. The evaluation of an automated digital image system, Nextslide Digital Review Network, for examination of peripheral blood smears. The American Society for Clinical Pathology 2010 Annual Meeting, 2010. e-Pub 2010.

Book Chapters

1. Ok CY, Vega F, Wang SA. Nodal T-Follicular Helper Cell Lymphoma. In: Flow Cytometry in Hematolymphoid Neoplasms: A Comprehensive and Practical Guide to Diagnosis. Cambridge University Press, 2026.
2. Ok CY, Vega F, Wang SA. Other Nodal and Extranodal Mature NK/T-cell Lymphomas. In: Flow Cytometry in Hematolymphoid Neoplasms: A Comprehensive and Practical Guide to Diagnosis. 1st. Cambridge University Press, 2026.
3. Ok, CY, Hasserjian, RP. Leukocytosis: Neutrophilia, Basophilia, and Blasts. In: Diagnosis of Blood and Bone Marrow Disorders. Springer, 135-170, 2018.
4. Ok CY, Singh RR, Salim AA. Single-Cell Quantitative PCR: Advances and Potential in Cancer Diagnostics. In: Methods Mol Biol - Clinical Applications of PCR. Springer, 153-9, 2016.

Letters to the Editor

1. Jain P, Nomie K, Kotlov N, Segodin V, Hill H, Ok CY, Fetooh A, Kanagal-Shamanna R, Vega F, Bagaev A, Fowler N, Flowers CR, Wang M. Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma. Blood Cancer J 13: 156, 2023.
2. Thakral B, Daver N, Tang Z, Patel KP, Ok CY, Loghavi S, Khoury J, Alotaibi A, Konopleva M, Yilmaz M, Medeiros LJ. Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leukemia and Lymphoma 61: 3243-3246, 2020.
3. Romaguera JE, Lee HJ, Tarapore R, Prabhu V, Allen J, Schalop L, Zloza A, Ok CY, Sadimin ET, Schenkel J, Badillo M, Wang M. Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment. Br J Haematol 185: 133-136, 2019.